Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis.
Kollmann K, Heller G, Schneckenleithner C, Warsch W, Scheicher R, Ott RG, Schäfer M, Fajmann S, Schlederer M, Schiefer AI, Reichart U, Mayerhofer M, Hoeller C, Zöchbauer-Müller S, Kerjaschki D, Bock C, Kenner L, Hoefler G, Freissmuth M, Green AR, Moriggl R, Busslinger M, Malumbres M, Sexl V. Kollmann K, et al. Cancer Cell. 2013 Aug 12;24(2):167-81. doi: 10.1016/j.ccr.2013.07.012. Cancer Cell. 2013. PMID: 23948297 Free PMC article.
JunB is a gatekeeper for B-lymphoid leukemia.
Ott RG, Simma O, Kollmann K, Weisz E, Zebedin EM, Schorpp-Kistner M, Heller G, Zöchbauer S, Wagner EF, Freissmuth M, Sexl V. Ott RG, et al. Among authors: kollmann k. Oncogene. 2007 Jul 19;26(33):4863-71. doi: 10.1038/sj.onc.1210285. Epub 2007 Feb 12. Oncogene. 2007. PMID: 17297445
High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia.
Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, Hölbl A, Gleixner KV, Dworzak M, Mayerhofer M, Hoermann G, Herrmann H, Sillaber C, Egger G, Valent P, Moriggl R, Sexl V. Warsch W, et al. Among authors: kollmann k. Blood. 2011 Mar 24;117(12):3409-20. doi: 10.1182/blood-2009-10-248211. Epub 2011 Jan 10. Blood. 2011. PMID: 21220747 Free article.
PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas.
Laimer D, Dolznig H, Kollmann K, Vesely PW, Schlederer M, Merkel O, Schiefer AI, Hassler MR, Heider S, Amenitsch L, Thallinger C, Staber PB, Simonitsch-Klupp I, Artaker M, Lagger S, Turner SD, Pileri S, Piccaluga PP, Valent P, Messana K, Landra I, Weichhart T, Knapp S, Shehata M, Todaro M, Sexl V, Höfler G, Piva R, Medico E, Ruggeri BA, Cheng M, Eferl R, Egger G, Penninger JM, Jaeger U, Moriggl R, Inghirami G, Kenner L. Laimer D, et al. Among authors: kollmann k. Nat Med. 2012 Nov;18(11):1699-704. doi: 10.1038/nm.2966. Epub 2012 Oct 14. Nat Med. 2012. PMID: 23064464 Free article.
CDK6 and p16INK4A in lymphoid malignancies.
Kollmann K, Sexl V. Kollmann K, et al. Oncotarget. 2013 Nov;4(11):1858-9. doi: 10.18632/oncotarget.1541. Oncotarget. 2013. PMID: 24161991 Free PMC article. No abstract available.
Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2.
Grundschober E, Hoelbl-Kovacic A, Bhagwat N, Kovacic B, Scheicher R, Eckelhart E, Kollmann K, Keller M, Grebien F, Wagner KU, Levine RL, Sexl V. Grundschober E, et al. Among authors: kollmann k. Leukemia. 2014 Sep;28(9):1918-22. doi: 10.1038/leu.2014.152. Epub 2014 May 5. Leukemia. 2014. PMID: 24791858 Free PMC article. No abstract available.
76 results